NCT02942914View on ClinicalTrials.gov

A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 20, 2016

Primary Completion Date

October 18, 2017

Study Completion Date

October 18, 2017

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

LY3209590

Administered SC

DRUG

Placebo

Administered SC

DRUG

Insulin Glargine

Administered SC

Trial Locations (1)

41460

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Neuss

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02942914 - A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes | Biotech Hunter | Biotech Hunter